Apimeds Pharmaceuticals US, Inc. acquires MindWave (2026)

Deal facts

Buyer: Apimeds Pharmaceuticals US, Inc.
Target: MindWave
Deal value: Not disclosed
Announced: 17 February 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: Not stated

Sources

SEC_EDGAR_8K

What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

30 Sept 2025CompletedClosed
Apimeds Pharmaceuticals US, Inc. completes acquisition of MindWave
Item 9.01 of Form 8-K in connection with the reverse merger transaction previously reported under Item 2.01 (Completion of Acquisition or Disposition of Assets) in the Original Report. This Amendment does not reflect any events occurring after the filing of the Original Report and does not amend or update any disclosures contained therein, except as expressly provided herein. 1 Item 2.01 Completio
Source

OpinionExit Mode editorial

We see a clear signal in the completion of the merger between Apimeds Pharmaceuticals US, Inc and MindWave. Both entities operate within the US healthcare sector, and the structure is defined as a merger of equals. This is not a standard acquisition where one party absorbs the other. Instead, the deal implies a strategic consolidation of capabilities, likely aimed at creating a more resilient entity capable of navigating the complex regulatory landscape of the American pharmaceutical market. The announcement date of 17 February 2026 marks the formal recognition of this new combined strength.

For the SME founder reading this, the choice of a merger of equals structure carries distinct implications for control and governance. Unlike a traditional sale where the buyer dictates terms, this model requires a high degree of alignment between the two founding teams regarding culture, strategy, and operational integration. The absence of a disclosed value in the public record is typical for such transactions, often relying on share swaps rather than cash consideration. This mechanism shifts the focus from a one-off exit to a long-term partnership where both parties share the risks and rewards of the combined entity. It demands that founders remain deeply engaged post-completion rather than stepping back.

The regulatory context for any US healthcare merger of this nature invariably involves scrutiny from the Federal Trade Commission or the Department of Justice to ensure competition is not stifled. While the deal is already marked as completed, the path to this point would have required rigorous due diligence on intellectual property portfolios and pipeline assets. The success of this integration now hinges on the ability to merge distinct R&D workflows without losing the agility that characterised both original companies. We believe this structure offers a viable path for founders who wish to scale without surrendering their strategic vision to a larger corporate parent.

You should review your current shareholder agreement to identify change-of-control covenants that might trigger if you ever pursue a similar merger of equals. Ensure your board has the authority to negotiate governance structures that protect your operational autonomy during the integration phase, as this is where most such deals face friction.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More merger of equals deals More from Apimeds Pharmaceuticals US, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

23 June 2026In reviewHealthcare

Fortitude Mining Holdings, Inc. to acquire HeartSciences Inc.

Fortitude Mining Holdings, Inc. and HeartSciences Inc. have agreed to merge in a transaction structured as a merger of equals. Both companies are based in the United Sta…

Buyer: Fortitude Mining Holdings, Inc.
Target: HeartSciences Inc.
Deal value: Not disclosed
Deal type: merger of equals

Read deal Healthcare deals merger of equals deals United States deals

5 March 2024CompletedHealthcare

QT Imaging Holdings, Inc. to acquire QT Imaging, Inc.

QT Imaging Holdings, Inc. and QT Imaging, Inc. have agreed to merge in a transaction valued at undisclosed terms. The deal structure involves consideration through share…

Buyer: QT Imaging Holdings, Inc.
Target: QT Imaging, Inc.
Deal value: Not disclosed
Deal type: merger of equals

Read deal Healthcare deals merger of equals deals United States deals

15 October 2026CompletedHealthcare

Cronos Group Inc. to acquire CanAdelaar B.V.

Cronos Group Inc. has agreed to acquire CanAdelaar B.V. in a strategic acquisition within the healthcare sector. The Canadian buyer will purchase the Dutch target for a…

Buyer: Cronos Group Inc.
Target: CanAdelaar B.V.
Deal value: EUR 57,500,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Netherlands deals

14 October 2026Firm intentionHealthcare

Laboratory Corporation of America Holdings to acquire BioReference Health, LLC

Laboratory Corporation of America Holdings has agreed to acquire BioReference Health, LLC in a transaction valued at 722 million US dollars. The deal, announced on 14 Oc…

Buyer: Laboratory Corporation of America Holdings
Target: BioReference Health, LLC
Deal value: USD 722,000,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

14 October 2026CompletedHealthcare

Silo Pharma, Inc. to acquire Larry King

Silo Pharma, Inc. has completed the acquisition of assets from Larry King. The transaction, which was announced on 14 October 2026, was finalized on 13 October 2026. Bot…

Buyer: Silo Pharma, Inc.
Target: Larry King
Deal value: Not disclosed
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

Buyer history